• Higher IFP linked with treatment resistance and metastasis. • Identification of IFP could dictate appropriate use of aggressive therapies. • Further assessment of noninvasive measurement needed.
Conference to highlight new developments in disparities research. San Diego, Calif. , oct. 27-30, 2012.
• Model predicts immediate treatment confers only modest extension of life. • Surveillance affords patients years of treatment-free life. • Data support continued adoption of surveillance approach.
• Denosumab decreased tumor presence in the entire cohort. • Some patients experienced bone regrowth. • Drug could be first medical alternative to radical surgery.
• Viral load and cancer-specific gene expression identified as potential markers. • Head-to-head biomarker comparison is crucial.
Conference to highlight new developments in cancer prevention, Anaheim, Calif. , Oct. 16-19, 2012.
• PARP inhibitors are promising treatments for BRCA-associated familial breast and ovarian cancers. • They may have activity outside of familial cancers independent of DNA repair defects.
Following successful SU2C telethon, new details released regarding multi-million dollar childhood cancer research initiative.
Report details astounding return on investment and calls on Congress to act.
• If validated, may have the potential to produce first targeted therapy for this disease. • Molecular profile of small cell lung cancer distinct from nonsmall cell lung cancer.
The nomination deadline is 4 p.m. ET on Wednesday, Oct. 10, 2012.
• Patients with oral lesions can be grouped according to risk level. • Two out of every three high-risk patients progressed to cancer. • Follow-up and treatment could be tailored to a patient’s risk level.
The nomination deadline is 4 p.m. on Wednesday, Oct. 3, 2012.
The nomination deadline is 4 p.m. ET on Wednesday, Sept. 26, 2012.
The deadline for nominations is Sept. 6, 2012.
• Disease has high heterogeneity. • First-line chemosensitivity associated with subsequent chemoresistance. • Gene identified that may predict chemoresistance.
• Denosumab reduced bone-related complications and need for radiation therapy. Treatment improved health-related quality of life. • May replace standard bisphosphonate treatments like zoledronic acid.
• In a mouse xenograft model, TRPM7 drives breast cancer cell metastasis. • Class of proteins exemplified by TRPM7 should be explored as a potential therapeutic target.
Research efforts will investigate DNA-guided personalized cancer treatment approaches.
New senior editorial team announced.
• Immune cell activation seen in skin metastases from melanoma patients. • Structures supported active B lymphocyte responses.
• Lack of IDO protein reduced tumor burden in primary and metastatic lung cancer models. • In both models, loss of IDO improved survival. • Mechanisms by which IDO promoted tumorigenesis were identified.
Grant nominations are now open: deadline is Tuesday, August 21, 2012.
Law will allow the FDA to use innovative approaches to provide lifesaving treatments and cures.
• Risk of basal cell carcinoma and coffee intake inversely associated. • No association with risk of other forms of skin cancer, including melanoma. • Caffeine most likely component of coffee responsible for the effect.
• BAY 86-9766 offers survival benefit in mouse model of pancreatic cancer. • Treatment yields remarkable tumor regression rapidly. • Therapy effective in mice with advanced tumors.
• A high-fat/calorie diet speeds development of precancerous lesions in mice. • Diet produces obese mice with pancreatic inflammation. • Human obesity may promote pancreatic cancer development.
• KRAS protein is a key driver of most cases of pancreatic cancer. • KRAS, working via leukemia inhibitory factor, promotes the generation and maintenance of pancreatic cancer stem cells. • LIF shows promise as a target for pancreatic cancer treatment.
• High levels of hypoxia in xenografted pancreatic tumors predict aggressive growth and enhanced metastatic potential. • Treatment efficacy of the hypoxia-targeting prodrug TH-302 depended on level of hypoxia and tumor growth rate. • Results provide additional rationale for ongoing clinical trials with TH-302.
• Variant of vitamin D receptor gene associated with higher overall survival. • The variant increases levels of vitamin D receptor expression in in vitro assays. • Study refocuses attention on role of the vitamin D pathway in affecting the disease course.
• Cancer stem cells sensitive to metabolic reprogramming with metformin. • Metformin effectively combined with standard pancreatic treatments. • Approach ready for clinical trials.
• Forty weak biomarkers must be identified. • Disease heterogeneity makes single biomarker diagnostics problematic.
• Combining erlotinib with bevacizumab, capecitabine and radiation is well tolerated by pancreatic cancer patients. • Treatment enabled some patients with previously unresectable tumors to have their tumors surgically removed. • The encouraging median survival indicates the combination has promise as a potential new treatment option.
• Levels of a fusion product of the SLC45A3 and ELK4 genes correlated with prostate cancer disease progression. • The fusion product controlled proliferation of prostate cancer cell lines. • An unusual pathway and not chromosomal rearrangement led to fusion product expression.
• RLIP76 expression is elevated in pancreatic cancer cells. • Blocking RLIP76 shrinks human pancreatic tumors implanted in mice. • RLIP76 plays a key role in pancreatic cancer cell resistance to chemotherapy and radiation.
• New approach has potential to change the way pancreatic cancer is treated. • GDC-0449 targets the Hedgehog signaling pathway. • Inhibiting this pathway may improve the efficacy of chemotherapy.
• Study supports link between high sun exposure and lower pancreatic cancer risk. • History of skin cancer and sun-sensitive skin type decreased pancreatic cancer risk.
• Severe pain is a common symptom of pancreatic cancer. • Levels of four neurotrophic factors were elevated in a pancreatic cancer model. • Nerve bundles in the pancreas were larger and physical activity lower.
AACR President Frank McCormick, Ph.D., F.R.S., D.Sc. (hon.), will serve on a top-tier panel of expert witnesses tomorrow, June 19, when the Senate Cancer Coalition convenes a congressional forum, “Preventing and Treating Breast Cancer in the 21st Century: Seeking the Right Treatment at the Right Time.”
• JAK3 mutations detected in 35 percent of NK/T-cell lymphoma patients tested. • Mutations increased growth of cultured NK/T-cell lymphoma cell lines. • JAK inhibitor increased cell death, suggesting a new therapeutic approach.
Leaders in cancer community to focus on how we define value, address need for health care cost containment, and sustain innovation to turn the tide against cancer
The Personalized Medicine Coalition, American Association for Cancer Research, and Feinstein Kean Healthcare are convening the Turning the Tide Against Cancer Through Sustained Medical Innovation national conference to consider the status and future of cancer innovation and personalized medicine. While recent scientific advances have generated both excitement and challenges in preventing, detecting, diagnosing, and treating cancer, there is an increasing recognition that our national policies are far from optimal in this new era of rapidly advancing personalized oncology.
• Final phase III trial analyses substantiate interim results that led to FDA approval. • Crossover trial design worked and benefitted patients. • Long-term overall survival benefit estimated with no new adverse events.
Tobacco use is the leading preventable cause of premature death in the United States. It causes no fewer than 18 different types of cancer and is responsible for nearly a third of all cancer deaths. Every conceivable method should be employed to combat this preventable epidemic, and that is why the American Association for Cancer Research strongly supports Proposition 29, The California Cancer Research Act.
The American Association for Cancer Research is pleased to announce that it has received three coveted 2012 Hermes Creative Awards for its two most recent Annual Meeting videos and one video highlighting the AACR Cancer Progress Report 2011.
• Study indicates relationship between weight loss and cancer risk. • Patients had a manageable goal of 10 percent weight loss. • Participants were overweight or obese, postmenopausal women.
• Patients with lung cancer and KRAS mutation responded well to antifolate therapy. • Response linked to downregulation of KRAS expression. • Downregulation may render cells more susceptible to chemotherapeutic drug.
• Patients with nonprogressive disease had improved survival rates. • Five-year survival rate for stage 3B/4 patients was 50 percent.
• High hormone levels linked to longer survival regardless of treatment. • Biomarker provided meaningful method for patient stratification. • Data should inform future clinical trial design.
• Intake associated with decreased mortality and recurrence rates. • Dose–response relationship observed. • Researchers recommend survivors eat more cruciferous vegetables.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right